vVardis Holding

Our mission is to create a world where cavity treatment is pain-free, regenerative and accessible to all. We believe, drawing on our industry experience, market understanding and extensive clinical evidence, that we have created a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth. Our proprietary peptide-enabled technology platform, Curodont®, delivers an early therapeutic solution for tooth decay, the world’s most prevalent non-communicable disease, addressing a massive global healthcare need that has historically lacked effective early-intervention medical treatment options. Our flagship Curodont® products—Curodont® Repair Fluoride Plus, which is currently sold in the United States and generates the vast majority of our revenues, and Curodont® Repair, which is currently sold in our other markets—are based on proprietary, peptide-containing formulations that complement the patient’s natural biology to help it stop the progression of early-stage cavities, preserve natural tooth structure and repair damaged enamel in early-stage cavities, establishing a new drill-free restorative category that we believe aligns clinical and economic incentives for patients, dental practitioners and payors.